With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.914988-10-6,tert-Butyl 3-cyano-4-oxopiperidine-1-carboxylate,as a common compound, the synthetic route is as follows.
914988-10-6, A mixture of tert-butyl 3-eyano-4-oxopiperidine- I -carboxylate (310 g, 1.38 mol) and hydrazine mono-hydrate (140 mL, 2.08 mol) in EtOH (1.5 L) was heated to 60 C for 2 h. The mixture was concentrated in vacuo to give the crude product that was dissolved inEtOAc (1 L) and washed with water (1 L x 2), The organic layer was dried over anhydrousNa2SO4, filtered and concentrated in vacuo to afford the title compound (230 g, 70%) as acolorless solid, ?H NMR (400 MHz, CD3OD) 6 4.28 (s, 211), 3.66 -3.63 (m, 211), 2.62 – 2.59(m, 211), 1.49 (s, 9H).
As the paragraph descriping shows that 914988-10-6 is playing an increasingly important role.
Reference：
Patent; GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC.; ROMERO, F. Anthony; MAGNUSON, Steven; PASTOR, Richard; TSUI, Vickie Hsiao-Wei; MURRAY, Jeremy; CRAWFORD, Terry; ALBRECHT, Brian, K.; COTE, Alexandre; TAYLOR, Alexander, M.; LAI, Kwong Wah; CHEN, Kevin, X.; BRONNER, Sarah; ADLER, Marc; EGEN, Jackson; LIAO, Jiangpeng; WANG, Fei; CYR, Patrick; ZHU, Bing-Yan; KAUDER, Steven; (0 pag.)WO2016/86200; (2016); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem